Form 4: CytomX Therapeutics Director Zhen Su Acquires 38,000 Stock Options

Director Zhen Su acquired 38,000 stock options in CytomX Therapeutics on May 15, 2024, according to a Form 4 filing with the SEC.

Summary

• On May 15, 2024, Zhen Su, a director of CytomX Therapeutics, Inc., acquired 38,000 stock options with an exercise price of $1.96.
• The options vest on the earlier of the first anniversary of the grant date or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
• Following the transaction, Zhen Su directly owns 38,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice for director compensation.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders, as it aligns the director's interests with those of the shareholders.

Key Dates